SCHEMBL4911522

SCHEMBL4911522

O=C(Nc1cccc2sc(Nc3ccccc3)nc12)c1c(F)cc(F)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
ALDH1A1 P00352 5/20 0.49
HPGD P15428 4/20 0.49
GAA P10253 5/20 0.46
LMNA P02545 5/20 0.46
NPC1 O15118 13/20 0.45
RAB9A P51151 12/20 0.45
SMN1; SMN2 Q16637 7/20 0.45
HTT P42858 2/20 0.45
AGTR1 P30556 1/20 0.45
OPRK1 P41145 1/20 0.45
PKM P14618 1/20 0.45
KDM4E B2RXH2 4/20 0.44
PRNP P04156 1/20 0.44
POLB P06746 2/20 0.43
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921076 0.92 MAPT (0.60) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4916206 0.83 MAPT (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4917456 0.83 KMT2A (0.48) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4908696 0.83 NPC1 (0.52) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL4918411 0.83 LCK (0.46) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4919944 0.82 NPC1 (0.51) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4913799 0.81 NPC1 (0.44) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4908770 0.80 DYRK1A (0.53) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4917276 0.80 KMT2A (0.52) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL14006480 0.80 TMIGD3 (0.58) MAPTMEN1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US claimed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 MAPT 1314/4885MEN1 3736/4885KMT2A 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.